Table 2.
Pathway analysis of regulatory patterns of genes dysregulated in each MEF2 knockdown
Shown is IPA canonical pathway analysis of genes dysregulated in the same direction in each treatment (shared) and pathways dysregulated in the same direction by Mef2a and -c shRNA treatment or Mef2c and -d shRNA treatment (MEF2A/C or MEF2C/D) or in the same direction by Mef2a and -d shRNA treatment (MEF2A/D).
| Canonical pathway | p | Ratio |
|---|---|---|
| Shared | ||
| Hepatic fibrosis/hepatic stellate cell activation | 5.23E−04 | 8:183 (0.044) |
| Phenylalanine degradation I (aerobic) | 5.80E−04 | 2:4 (0.50) |
| Serine biosynthesis | 9.75E−04 | 2:5 (0.40) |
| Superpathway of serine and glycine biosynthesis I | 2.02E−03 | 2:7 (0.286) |
| Antiproliferative role of TOB in T-cell signaling | 2.16E−03 | 3:26 (0.115) |
| MEF2A/D | ||
| Cell cycle control of chromosomal replication | 1.64E−09 | 8:27 (0.296) |
| Role of CHK proteins in cell cycle checkpoint control | 8.27E−06 | 7:55 (0.127) |
| Factors promoting cardiogenesis in vertebrates | 3.24E−05 | 8:92 (0.087) |
| GADD45 signaling | 1.03E−04 | 4:19 (0.210) |
| DNA damage-induced 14-3-3 signaling | 1.03E−04 | 4:19 (0.210) |
| MEF2A/C | ||
| Ephrin receptor signaling | 9.52E−03 | 3:174 (0.017) |
| Glycerol-3-phosphate shuttle | 1.00E−02 | 1:4 (0.250) |
| Melatonin degradation II | 1.00E−02 | 1:4 (0.250) |
| Ephrin B signaling | 1.45E−02 | 2:73 (0.027) |
| Glycerol degradation I | 1.50E−02 | 1:6 (0.167) |
| MEF2C/D | ||
| Type I diabetes mellitus signaling | 1.01E−03 | 3:110 (0.027) |
| Role of JAK2 in hormone-like signaling | 1.70E−03 | 2:34 (0.059) |
| Role of pattern recognition receptors in recognition of bacteria and viruses | 1.91E−03 | 3:137 (0.022) |
| Interferon signaling | 1.91E−03 | 2:36 (0.056) |
| Activation of IRF by cystolic pattern recognition receptors | 5.57E−03 | 2:62 (0.032) |